← Leaderboards
Sudeshna Roy
University Of Mississippi
$1,926,297
Attributed
$2,692,655
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,692,655 · 3
By mechanism
R01$1,532,717 · 1
R35$748,846 · 1
R21$411,092 · 1
Top collaborators
- Christina Leigh Stallings2 shared
Most similar at University Of Mississippi
Same institution · by research overlap
- David Cole Stevens$1,908,090
Others in their field
Other Emerging Leaders on “Antibiotics”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
- Bruce Blough · Research Triangle Institute$19,637,160
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
AntibioticsPropertyStructureInsightCostAreaBiologicalSmall MoleculeCell WallEnzymesAnti-Bacterial AgentsResistant StrainMulti-Drug ResistanceAntibiotic ResistanceAntibiotic TherapyDrug-SensitiveDrug Resistance In TuberculosisCombatMacrophageMycobacterium TuberculosisInfectionAnabolismBiological AvailabilityIn Vivo
Grant awards (7)
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis$745,546
R01 · FY2025 · AI
Expanding the small molecule toolbox through novel applications of fluorinated alkenes$231,000
R35 · FY2025 · GM · contact PI
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis$787,171
R01 · FY2024 · AI
Expanding the small molecule toolbox through novel applications of fluorinated alkenes$231,000
R35 · FY2024 · GM · contact PI
Expanding the small molecule toolbox through novel applications of fluorinated alkenes$286,846
R35 · FY2023 · GM · contact PI
Target-based chemotherapeutics development against Mycobacterium tuberculosis$218,138
R21 · FY2020 · AI · contact PI
Target-based chemotherapeutics development against Mycobacterium tuberculosis$192,954
R21 · FY2019 · AI · contact PI